ER/PR(+), HER2(-) BREAST CANCER

Clinical trials for ER/PR(+), HER2(-) BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new ER/PR(+), HER2(-) BREAST CANCER trials appear

Sign up with your email to follow new studies for ER/PR(+), HER2(-) BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation

Disease control Recruiting now

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

Matched conditions: ER/PR(+), HER2(-) BREAST CANCER

Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

ER/PR(+), HER2(-) BREAST CANCER

Get alerted when new ER/PR(+), HER2(-) BREAST CANCER trials appear

First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation